아칸소의 주요우울장애 임상 시험
주요우울장애 관련 연구 13개가 아칸소 내 여러 지역에서 참여자를 모집하고 있습니다.
아칸소의 도시
공식 연구 텍스트(영어)
A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)
- Preferred Research Partners, Inc., Little Rock
피험자 모집 중3상
18세 ~ 74세 · 모든 성별 · 2026. 11. 9. 업데이트됨 · NCT07592689Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
- SanRo Clinical Research Group LLC WCG Clinical Network, Bryant
피험자 모집 중3상
18세 ~ 74세 · 모든 성별 · 2026. 11. 3. 업데이트됨 · NCT06559306A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder
- SanRo Clinical Research Group LLC WCG Clinical Network, Bryant
피험자 모집 중3상
18세 ~ 74세 · 모든 성별 · 2026. 11. 3. 업데이트됨 · NCT07573176Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- Neurocrine Clinical Site, Bryant
- Neurocrine Clinical Site, Little Rock
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 11. 2. 업데이트됨 · NCT06966401Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder
- Woodland Research Northwest (ERG), Rogers
피험자 모집 중2상
18세 ~ 70세 · 모든 성별 · 2026. 10. 28. 업데이트됨 · NCT07226661Study of ALTO-300 in MDD
- Site 193, Rogers
피험자 모집 중2상
18세 ~ 70세 · 모든 성별 · 2026. 10. 26. 업데이트됨 · NCT05922878A Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression
- Draig Clinical Site, Little Rock
피험자 모집 중2상
18세 ~ 75세 · 모든 성별 · 2026. 10. 14. 업데이트됨 · NCT07610473A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression
- Draig Clinical Site, Bentonville
- Draig Clinical Site, Little Rock
피험자 모집 중2상
18세 ~ 75세 · 모든 성별 · 2026. 10. 8. 업데이트됨 · NCT07300969Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder
- Vanda Investigational Site, Little Rock
피험자 모집 중3상
18세 ~ 65세 · 모든 성별 · 2026. 9. 24. 업데이트됨 · NCT06830044A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
- Neurocrine Clinical Site, Bryant
피험자 모집 중4상
18세 이상 · 모든 성별 · 2026. 9. 18. 업데이트됨 · NCT07105111NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- Neurocrine Clinical Site, Bryant
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 8. 11. 업데이트됨 · NCT06911112A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder
- Preferred Research Partners /ID# 279206, Little Rock
- Woodland International Research Group /ID# 277605, Little Rock
피험자 모집 중2상
18세 ~ 65세 · 모든 성별 · 2026. 6. 15. 업데이트됨 · NCT07276997Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- Neurocrine Clinical Site, Little Rock
피험자 모집 중3상
18세 이상 · 모든 성별 · 2025. 10. 29. 업데이트됨 · NCT06786624ClinicalTrials.gov 출처, 2026. 11. 15. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.